Consortium for Pharmaceutical Education and Practice

Consortium for Pharmaceutical Education and Practice Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Consortium for Pharmaceutical Education and Practice, Hospital Road, Taluk Headquarters Hospital, Peermade.

The Consortium for Pharmaceutical Education and Practice (CPEP) is a professional hub for Pharmacy Practising Professionals to update and educate on their day to day assignments.

27/08/2026

MARKED HYPERGLYCEMIA: WHEN TO INTENSIFY

When should glucose-lowering therapy move beyond routine adjustment?

📌 Start with the individualized A1C goal.

If A1C is ≥1.5% above the individualized goal, many patients will need combination therapy or a more potent glucose-lowering approach.

🚨 When hyperglycemia is severe — A1C >10% or blood glucose ≥300 mg/dL — consider insulin, particularly when symptoms or catabolic features are present.

⚠️ Watch for:
Polyuria • Polydipsia • Unexpected weight loss • Ketosis/ketonemia • Catabolism

When severe hyperglycemia or a crisis is absent, GLP-1–based therapy is generally preferred to insulin for initial or add-on glucose lowering.

The clinical message: **recognize the degree of hyperglycemia, identify red flags, and intensify therapy without therapeutic inertia.**

💾 Save this decision pathway for clinical reference.
↗️ Share with a colleague involved in diabetes care.

Source: American Diabetes Association. Standards of Care in Diabetes—2026. Section 9.

27/08/2026

DURABILITY OF GLYCEMIC CONTROL

How long can glycemic control be maintained with continued treatment?

The GRADE trial highlights an important clinical distinction: a treatment’s initial glucose-lowering effect is not the same as its durability over time.

📊 Mean time to the primary metabolic outcome:
• Liraglutide — 882 days
• Insulin glargine — 861 days
• Glimepiride — 809 days
• Sitagliptin — 697 days

Longer time to glycemic failure indicates greater durability of glycemic control in this trial.

Importantly, these numbers do NOT represent the duration of drug action. They represent the mean time until the predefined trial endpoint — HbA1c ≥7%, confirmed at the next visit after previously being

27/08/2026

TIME TO GLYCEMIC EFFECT ⏱️

How quickly should you expect glucose lowering to begin?

Antidiabetic therapies differ in how quickly their glucose-lowering effects become apparent. Understanding the expected time course helps set realistic expectations and supports timely reassessment.

⚡ RAPID
Insulin → rapid glucose-lowering effect; particularly useful when prompt control is required.

🟠 EARLY
Sulfonylureas / meglitinides → rapid insulin-secretagogue effect.
SGLT2 inhibitors → glucose lowering begins early and continues with ongoing therapy.

🔵 PROGRESSIVE
GLP-1 RA / dual GIP–GLP-1 RA → effect develops with initiation and dose optimization.

🟣 LONGER-TERM ASSESSMENT
Metformin and DPP-4 inhibitors → progressive glucose-lowering effects assessed over subsequent weeks.

📌 IMPORTANT:
If A1C is ≥1.5% above the individualized goal, many patients will require dual-combination therapy or a more potent glucose-lowering approach.

Don't allow therapeutic inertia to delay intensification when individualized goals are not being met.

💾 Save this for a quick clinical reference.
↗️ Share with a colleague involved in diabetes care.

Source: American Diabetes Association. Standards of Care in Diabetes—2026. Section 9.

27/08/2026

Sulfonylureas vs meglitinides — both stimulate insulin secretion, but their clinical profiles are not interchangeable.

💊 SULFONYLUREAS
• Longer duration
• Usually once or twice daily
• Low cost and established efficacy
• Hypoglycemia and weight gain remain important limitations
• Glyburide is generally not recommended in CKD

💊 MEGLITINIDES
• Shorter duration
• Taken before meals
• Dose can be omitted when a meal is skipped
• Greater meal-time flexibility
• Hypoglycemia risk and weight gain still remain

📌 The practical distinction:
Sulfonylureas offer simpler, lower-cost dosing.
Meglitinides offer shorter action and greater flexibility around meals.

The choice should consider renal function, eating pattern, hypoglycemia risk, cost, and treatment goals.

💾 Save this comparison for quick clinical reference.
↗️ Share it with a colleague involved in diabetes care.

Source: American Diabetes Association. Standards of Care in Diabetes—2026. Section 9.

26/08/2026

When Can We Trust Serum Creatinine?

Serum creatinine reflects GFR—but it is also influenced by non-GFR factors.

So don't stop at the number. Ask whether the creatinine value is actually a reliable reflection of GFR in this patient.

A PRACTICAL CLINICAL ALGORITHM

01 | IS KIDNEY FUNCTION STABLE?
→ YES: Creatinine-based eGFR is generally more interpretable.
→ NO / RAPIDLY CHANGING: ⚠️ Use caution; creatinine-based eGFR may not reliably reflect current GFR.

02 | IS CREATININE PRODUCTION TYPICAL?
Consider muscle mass, muscle wasting, amputation, diet, and creatine supplementation.
→ Major deviations can alter creatinine independently of GFR.

03 | COULD CREATININE HANDLING OR MEASUREMENT BE ALTERED?
Consider tubular secretion, medications, assay effects, and significant illness.
→ If present, interpret the estimate cautiously.

04 | DOES THE CLINICAL CONTEXT FIT THE NUMBER?

🟢 Stable kidney function + typical creatinine determinants + appropriate context
→ More likely to reflect GFR

🔴 AKI / unstable kidney function + major non-GFR determinants
→ Use caution

THE CLINICAL QUESTION

Don't ask only:

“Is the creatinine normal?”

Ask:

“Is this creatinine a reliable reflection of GFR in this patient?”

CPEP | Consortium for Pharmaceutical Education & Practice

26/08/2026

ANTIDIABETICS IN HEART FAILURE — which agents should we prefer, and which should we avoid?

In patients with type 2 diabetes and heart failure, drug selection should go beyond glucose lowering.

🟢 PREFERRED
SGLT2 inhibitors have demonstrated benefits across HFrEF and HFpEF, reducing worsening heart failure and cardiovascular events.

🟢 SPECIFIC PHENOTYPE
In T2D + obesity + symptomatic HFpEF, selected GLP-1 receptor agonists and dual GIP/GLP-1 RA therapies can provide additional HF and metabolic benefit.

🟠 USE WITH CONTEXT
Metformin may be continued in stable HF when renal function permits, but should be avoided in unstable or hospitalized HF.

DPP-4 inhibitors are generally CV neutral, but saxagliptin has an increased HF-hospitalization signal.

🔴 AVOID
Thiazolidinediones (pioglitazone, rosiglitazone) can cause fluid retention and worsen heart failure.

📌 Key clinical point:
When diabetes and heart failure coexist, choose therapy according to HF phenotype, renal function, cardiovascular risk, comorbidities, and patient-specific treatment goals—not HbA1c alone.

💾 Save this for clinical reference.
↗️ Share with a colleague involved in diabetes or heart-failure care.

Source: American Diabetes Association. Standards of Care in Diabetes—2026. Section 9.

SGLT2Inhibitors GLP1RA DiabetesManagement Cardiology Pharmacology Therapeutics MedicalEducation ClinicalMedicine HealthcareProfessionals CPEP

26/08/2026

How do antidiabetic drugs affect cardiovascular outcomes? 🫀

Not all glucose-lowering therapies are cardiovascularly equivalent.

🟢 ESTABLISHED CV BENEFIT
Selected SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated reductions in major cardiovascular outcomes in appropriate patients with T2D and established/high CV risk.

🔵 HEART FAILURE BENEFIT
SGLT2 inhibitors have the strongest and most consistent evidence for reducing heart-failure hospitalization and improving HF outcomes.

🟣 RENAL + CV PROTECTION
SGLT2 inhibitors and selected GLP-1 receptor agonists can provide benefits extending beyond glucose lowering.

🟠 CV NEUTRAL
DPP-4 inhibitors have generally demonstrated cardiovascular safety rather than cardiovascular benefit.

🔴 USE WITH CAUTION
TZDs can worsen fluid retention and heart failure; hypoglycemia with insulin and sulfonylureas can also influence cardiovascular risk.

One important distinction:
Tirzepatide has demonstrated substantial metabolic and weight benefits, but established ASCVD outcome benefit should not be assumed while cardiovascular outcome evidence is still evolving.

📌 The clinical takeaway:
When T2D coexists with ASCVD, heart failure, or CKD, drug selection should consider cardiovascular and renal outcomes—not HbA1c reduction alone.

💾 Save this for a quick cardiovascular pharmacotherapy reference.
↗️ Share with a colleague involved in diabetes care.

Source: American Diabetes Association. Standards of Care in Diabetes—2026. Sections 9 & 11.

SGLT2Inhibitors GLP1RA DiabetesManagement Pharmacology Therapeutics MedicalEducation ClinicalMedicine HealthcareProfessionals CPEP

26/08/2026

How does kidney function change the choice of antidiabetic therapy?

Renal function matters — not only for dose adjustment, but also for deciding which glucose-lowering agents can be initiated, continued, or avoided.

📌 QUICK eGFR GUIDE

🟢 ≥60 mL/min/1.73 m²
Most agents can be used without renal dose adjustment.

🟡 45–59
Continue/use metformin with appropriate dose reduction; monitor renal function. Other agents may require class-specific adjustment.

🟠 30–44
Metformin: maximum 1,000 mg/day with monitoring. Review sulfonylureas and DPP-4 inhibitor dosing; insulin may require dose reduction.

🔴 15–29
Metformin should not be initiated and should be discontinued if eGFR

26/08/2026

Which antidiabetic drugs carry the greatest risk of hypoglycemia?

Not all glucose-lowering therapies carry the same intrinsic hypoglycemia risk.

🔴 HIGHER RISK
• Insulin
• Sulfonylureas
• Meglitinides

🟢 LOW / MINIMAL RISK WHEN USED ALONE
• Metformin
• SGLT2 inhibitors
• DPP-4 inhibitors
• GLP-1 receptor agonists
• Dual GIP/GLP-1 RA
• TZDs
• α-glucosidase inhibitors

📍 KNOW THE THRESHOLDS

26/08/2026

Which antidiabetic drugs cause weight loss — and which cause weight gain?

Weight effect is an important part of choosing glucose-lowering therapy.

⬇️ WEIGHT LOSS
Tirzepatide: 12.8–14.7% ↓ body weight
Semaglutide 2.4 mg: 9.6% ↓ body weight
Other GLP-1 receptor agonists • SGLT2 inhibitors • Metformin

↔️ WEIGHT NEUTRAL
DPP-4 inhibitors • α-glucosidase inhibitors

⬆️ WEIGHT GAIN
Sulfonylureas / meglitinides • Thiazolidinediones • Insulin

📌 The clinical takeaway:
Antidiabetic therapy can move body weight in very different directions. Knowing the expected weight effect can help when individualizing treatment.

The magnitude of weight change varies with the agent, dose, treatment duration and patient characteristics.

💾 Save this as a quick reference for diabetes pharmacotherapy.

↗️ Share it with a colleague involved in diabetes care.

💬 Which antidiabetic class do you think has the most clinically important weight effect?

Source: American Diabetes Association. Standards of Care in Diabetes—2026, Sections 8 & 9.

Therapeutics MedicalEducation ClinicalMedicine HealthcareProfessionals CPEP

Address

Hospital Road, Taluk Headquarters Hospital
Peermade
685531

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm
Saturday 9am - 5pm

Telephone

+919895137331

Website

Alerts

Be the first to know and let us send you an email when Consortium for Pharmaceutical Education and Practice posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Consortium for Pharmaceutical Education and Practice:

Shortcuts

Share